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Abstract 
Purpose: To investigate the effects of triptergium glycosides (TG) on expressions of monocyte 
chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CTGF) in early diabetic 
nephropathy (DN) in rats, and explore its mechanism of renal protection. 
Methods: Thirty-two rats were divided into 4 groups: normal control (NC), DN, and DN-treated with TG 
(5 and 10 mg/kg/d) groups. After 8 weeks, body weight, blood glucose (BG), albumin (ALB), blood urea 
nitrogen (BUN), creatinine (SCr) and 24 h urinary total protein (UTP) of rats were determined. 
Additionally, expressions of CTGF, MCP-1 and ED-1 were detected by immunohistochemistry assay, 
while mRNA and protein expressions of CTGF and MCP-1 in kidney tissues were evaluated using 
reverse transcription-polymerase chain reaction (RT-PCR) and western blot technique. 
Results: BG, ALB, SCr, BUN and UTP in DN group were significantly increased (p < 0.01), compared 
with NC group. Compared with DN group, ALB (28.90 and 31.49 vs 23.13 g/L) and UTP (21.87 and 
18.91 vs 37.19 mg/24 h) were significantly changed in TG groups (p < 0.05). ED-1 positive cells were 
significantly increased in DN group (p < 0.01), compared with NC group, whereas treatment with TG 
significantly reversed the increase (1.67 and 1.41 vs 2.73 in glomeruli, 9.86 and 9.49 VS 13.18 in 
glomerular interstitial, p < 0.01). Proteins and mRNA expressions of CTGF and MCP-1 significantly 
increased (p < 0.01) in DN group, compared with NC group, while their expressions in TG groups were 
reversed. 
Conclusion: TG ameliorates renal injury in diabetic rats via decreasing MCP-1 and CTGF expressions 
and reducing macrophage activation. 
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Increasing clinical and animal studies have 
indicated that activation of the immune response 
and inflammatory mechanisms are important in 
the pathogenesis of diabetic nephropathy (DN), 
which is one of the chronic complications of 
diabetes [1]. It’s reported that chemokines, such 
as monocyte chemoattractant protein-1 (MCP-1) 
and connective tissue growth factor (CTGF), play 
important roles in the recruitment and activation 
of these immunocytes. Specifically, MCP-1 can 
cause extensive migration and infiltration of 
monocytes/macrophages in kidney actively 
involved in DN [2]. CTGF, a downstream effector 
of transforming growth factor-β1 (TGF-β1), 
stimulates mesangial cell proliferation and 
extracellular matrix (ECM) production and also 
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promotes the development of renal fibrosis, 
leading to renal pathological changes associated 
with DN [3].  
 
Triptergium glycoside (TG) is commonly used to 
treat DN based on its anti-inflammatory and 
immunosuppressive effects. However, the 
specific mechanism of TG’s renal protection is 
still not entirely clear. Therefore, the present 
study was designed to investigate the effect of 
TG on expressions of MCP-1 and CTGF in early 





Materials and chemicals 
 
TG was purchased from Fudan Forward Co. 
(Shanghai, China). Streptozotocin (STZ) was 
purchased from Sigma Co. (USA). The following 
reagents were purchased from Aobosen Co. 
(Beijing, China): rabbit anti-rat CTGF and MCP-1 
primary antibodies, mouse anti-rat ED-1 
monoclonal antibody, goat anti-rabbit IgG 
antibody, goat anti-mouse IgG antibody and DAB 
horseradish peroxidase color development kit. 
Trizol reagent was purchased from Invitrogen 
Co. (USA), and RT-PCR kit was purchased from 
Fermentas Co. (USA). CTGF, MCP-1 and β-actin 
primers were synthesized by Sangon Biotech. 
Co., Shanghai, China. All other reagents used 




Male Sprague Dawley (SD) rats (8-weeks old, 
weighing 180 - 200 g) were purchased from 
Experimental Animal Center of Bengbu Medical 
College (Anhui, China). All the animal protocols 
were established according to the generally 
accepted international rules strictly, and 
approved by the Animal Care and Use 




Thirty-two male SD rats were used in the present 
study. Diabetic rats were constructed by feeding 
a high-fat and high-sugar diet with 10 % lard, 20 
% sucrose and 3 % cholesterol for 4 weeks, and 
given a single intraperitoneal injection (ip) of 55 
mg/kg STZ in sodium citrate. Meanwhile, the rats 
in negative control group (NC group, n=8) were 
fed a normal diet, and injected an equal volume 
of citrate-citrate sodium buffer alone (ip). 
Diabetes was confirmed if the blood glucose 
(BG) value on the third day exceeded 16.7 
mmol/L after STZ injection. Moreover, DN was 
confirmed if the 24 h urinary total protein (UTP) 
values exceeded 30 mg, and the amount of 24 h 
urine was increased by 50 %, compared with 
before induction. 
  
After the DN rats were rendered diabetic, they 
were randomly divided into 3 groups, including 
DN group, and TG treatment groups [5 mg/kg/d 
(TG1) and 10 mg/kg/d (TG2)] (n = 8). TG (5 and 
10 mg/kg/d) was administered orally (ig) once a 
day for 8 weeks. Rats in the NC and DN groups 
received an equivalent volume of physiological 
saline per day (ig). During the experimental 
period, antidiabetic drugs were not applied. Body 
weight was measured weekly, and 24 h urine 
was collected after induction and analyzed at the 
end of the study. All the animals were sacrificed 
after hemospasia from the heart, and then blood 
samples were centrifuged to obtain serum. 
Serum samples were stored at -20 °C until 
analysis. The kidneys (right and left) were 
dissected out and fixed in 10 % formalin for 
histopathological analysis or fixed in 3.75 % 
pentanediol for transmission electron microscopy 
(TEM) assay. The rest of the kidney tissues were 
rapidly frozen with liquid nitrogen and stored at -
80 °C. 
 
Blood sampling and biochemical analysis 
 
By using the automatic biochemistry analyzer, 
blood and urine samples of rats were collected to 
determine the albumin (ALB), blood urea 
nitrogen (BUN), creatinine (SCr), UTP and other 
indicators. BG was measured using blood 
glucose monitor (Roche, Switzerland). 
 
Electron microscopy (EM) 
 
Tissue fragments (1 mm3)  were randomly taken 
from the kidney tissue and fixed in 3.75 % 
pentanediol at 4 °C for more than 4 h, washed 
five or six times with 0.1 M PBS, dehydrated in 
ethanol, and embedded in paraffin. For electron 
microscopy, blocks were trimmed and sections 
were cut at 80 - 90 nm, mounted on copper grids, 
aluminum citrate stained, and viewed under the 




The tissue sections were stained by hematoxylin 
and eosin (H&E) using standard histology 
procedures.  Immunohistochemical staining was 
performed using SABC kit according to the 
manufacturer’s instructions of commercial kits. 
The HPIAS-1000 high-resolution color graphic 
report of the pathology analysis system was used 
to analyze the average of the integral optical 
density (IDP). In each section, the number of ED-
1positive cells of 10 randomly selected 
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glomerular fields and 10 non-overlapping renal 
tubule-interstitial fields under high power 
magnification (400×) were counted. 
 
Western blot assay 
 
Western blot assay was performed to determine 
the expressions of MCP-1 and CTGF in kidney 
tissues. Kidney tissues were homogenized in 
RIPA lysis buffer supplemented with protease 
inhibitors and phosphatase inhibitors, using a 10 
% w/v ratio. Homogenates were then centrifuged 
for 15 min at 11,000 g and the supernatants were 
stored at −80 °C. Total proteins were extracted, 
and the concentration was determined using a 
BCA reagent kits. Thereafter, the proteins were 
separated by electrophoresis on sodium dodecyl 
sulfate/polyacrylamide gel (SDS-PAGE). 
Following transfer onto polyvinylidene fluoride 
(PVDF) membranes and blocking, the 
membranes were incubated overnight at 4 °C 
with the primary antibodies of MCP-1, CTGF and 
β-actin (1: 100). Following several washes in 
TBST, the PVDF membranes were subsequently 
incubated with horseradish peroxidase-
conjugated secondary antibody (1:1000) at 37 °C 
for 1 h. Thereafter, PVDF membrane was 
washed three times with TBST. The protein 
bands were detected by DAB staining, and the 
band densities quantified using Image J software 
(National Institutes of Health). For normalization 
of the loading, β-actin was used in the western 
blot assay. 
 
Reverse transcriptase polymerase chain 
reaction (RT-PCR) assay 
 
The mRNA expressions of MCP-1 and CTGF 
were analyzed by using RT-PCR determination. 
Total RNA was extracted from the renal cortical 
tissue by using TRIzol reagent. First strand 
cDNA were synthesized from 3 μg of total RNA. 
Sequences of the primers used in our 
investigation were as follows: for CTGF (160bp) 
5’-AGCTGCCTACCGACTGGAAGA-3’ (forward), 
5’-CTTCTCCAGCCTGCAGAAGGT-3 (reverse); 
for MCP-1(191bp) 5’-CCTGCTGCTACTCATT 
CAC-3’(forward), 5’-TCTCACTTGGTTCTGGTC-





PCR experiment was performed under the 
following selected conditions: first pre-
denaturation at 94 °C for 3 min followed by 30 
cycles of reactions of denaturation at 95 °C for 
50 s, annealing at 61.6 °C (CTGF), 56.2 °C 
(MCP-1), 63.6 °C (β-actin) for 50 s, extension at 
72 °C for 1 min and last extension for 10 min at 
72 °C. After amplification, the PCR products 
were evaluated by 1.5 % agarose gel 
electrophoresis. Bands were visualized and 
photographed on a UV trans-illuminator, and β-




Data were statistically analyzed by using SPSS 
16.0. Differences among the groups were 
analyzed by one-way analysis of variance 
(ANOVA). The t-test was used between each two 
groups. Data are presented as mean ± standard 





Effect of TG on fasting BG and urine 
biochemical parameters 
 
After the establishment of DN rat model, the DN 
rats appeared polydipsia, polyuria and 
emaciation. In the study, one rat in the TG1 
group (5 mg/kg) died. The body weights were 
significantly decreased in DN group, compared 
with the NC group. Before treatment with TG, the 
BG levels of the DN rats were increased by 
approximately 6-fold, compared with NC rats. 
After 8 weeks’ treatment, the BG levels of 
diabetic rats were decreased but still higher than 
the rats in NC group. However, treating these 
diabetic rats with TG at doses of 5 and 10 
mg/kg/d decreased the BG levels, compared with 
the DN group. The UTP levels of the rats were 
increased significantly after induction of DN, and 
treating these DN rats with TG decreased the 
UTP levels to some extent, compared with the 
DN group (p < 0.01). There was no statistically 
significant difference between each group with 
respect to SCr levels (Table 1). The BUN levels 
of the DN group was higher than the NC group (p 
< 0.01), and decreased significantly after 
treatment with TG (p < 0.01). The ALB level of 
TG2 group was higher than the NC group (p < 
0.01). 
 
Effect of TG on kidney pathology 
 
The effect of TG on the pathology of kidney was 
evaluated by H&E staining and EM analysis. 
Kidney of the rats in negative control group (NC 
group) stained with H&E showed normal renal 
histological structure of renal parenchyma and 
glomeruli (Figure 1A).  
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Table 1: Effect of TG treatment on fasting BG level and urine biochemical parameters of DN rats 
 
Parameter Statistics (Before intervention ) Statistics (After intervention) NC DN TG1 TG2 NC DN TG1 TG2 
Number (n) 8 8 7 8 8 8 7 8 
Body weight (kg) 0.43±0.03 0.41±0.02 0.39±0.03 0.39±0.06 0.57±0.08 0.26±0.02**## 0.39±0.06** 0.34±0.08*## 
BG (mmol/L) 5.24±1.05 30.99±2.56** 26.50±4.49** 28.34±4.07** 5.21±0.58 11.98±6.55*## 18.91±8.12** 16.18±4.91**## 
UTP (mg/24h) 12.09±1.75 35.31±3.14** 35.80±3.88** 35.89±5.29** 11.68±1.37 37.19±5.59** 21.87±6.92*#△△ 18.91±5.80##△△ 
SCr (μmol/L) 39.50±5.29 39.13±4.99 40.43±4.43 39.00±4.66 39.90±5.60 49.10±19.10 37.30±16.20 51.50±8.50 
BUN (mmol/L) 5.34±0.45 5.39±0.44 5.12±0.33 4.99±0.41 5.34±0.36 17.84±8.71** 9.88±3.69△△ 10.05±2.29△△ 
ALB (g/L) 23.44±3.72 23.24±3.74 24.09±3.67 24.21±3.64 23.85±4.02 23.13±4.41 28.90±1.81△△ 31.49±8.37**△△ 
Data are represented as mean ± SD; compared with the NC group, *p < 0.05, **p < 0.01; compared with the DN group, △p < 0.05, △△p < 0.01; compared with before/after 
intervention, #p < 0.05, ##p < 0.01 
 
 
Table 2: Effect of TG treatment on the expression of CTGF and MCP-1, and number of ED-1 positive cells in DN rats 
 
Parameters NC DN TG1 TG2 
CTGF positive area 0.1059±0.0131## 0.4613±0.1574** 0.2302±0.0214** ## 0.1354±0.0238##△ 
MCP-1 positive area 0.1143±0.0117## 0.4453±0.1519** 0.2059±0.0221*## 0.1749±0.0506## 
CTGF protein 0.139±0.011 0.334±0.038** 0.234±0.022**## 0.203±0.011*## 
MCP-1 protein 0.189±0.002 0.501±0.058** 0.254±0.019*## 0.249±0.011*## 
CTGF mRNA 0.2732±0.0234## 0.5989±0.0302** 0.4196±0.0267**## 0.2904±0.0651##△△ 
MCP-1 mRNA 0.2421±0.0219## 0.4335±0.0240** 0.3369±0.0324**## 0.2636±0.0220##△△ 
The number of   ED-1 positive cells (Glomeruli) 0.86±0.61 2.73±1.02** 1.67±0.74**## 1.41±0.71**##△ 
The number of   ED-1 positive cells (Glomerular interstitial) 2.14±1.08 13.18±2.19** 9.86±1.63**## 9.49±1.24**## 
Data are represented as mean ± SD; compared with the NC group,*p < 0.05 **p < 0.01; compared with the DN group, #p < 0.05, ##p < 0.01; compared with the TG1 group, △p < 
0.05, △△p < 0.01 
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Figure 1B showed kidney of rat from the positive 
control group (DN group) with slightly increased 
glomeruli, thickened glomerular basement 
membrane, widening mesangial, and vacuolated 
epithelial lining renal tubules. To some extent, 
treating DN rats with 5 mg/kg/d of TG in TG1 
group (Figure 1C) and a higher dose of TG (10 
mg/kg/d) in TG2 group (Figure 1D) restored the 
above-mentioned histopathological changes. 
 
Kidney of the rats in NC group observed under 
TEM showed normal renal histological structures 
(Figure 2A). Figure 2B showed kidney of rat from 
the DN group with thickened glomerular 
basement membrane, effacement of podocyte 
foot processes and reduction of the foot 
processes hiatus number. In Figure 2C and 2D, 
kidney tissue of DN rats in TG1 and TG2 treated 
with different doses of TG (5 and 10 mg/kg/d) 




Figure 1: H&E staining of Kidney in the different groups (400 × magnification); (A) NC group: Kidney of the rats 
showed normal renal histological structure of renal parenchyma and glomeruli; (B) DN group: Kidney of rat from 
the positive control group with slightly increased glomeruli, thickened glomerular basement membrane, widening 
mesangial and vacuolated epithelial lining renal tubules; (C) TG1 group: Treating DN rats with TG (5 mg/kg/d) 
reduced the above-mentioned histopathological changes; (D) TG2 group: Treating DN rats with a higher dose of 




Figure 2: Transmission electron micrographs of kidney in the different groups (7000× magnification); (A) NC 
group: Kidney of the rats showed normal renal histological structures; (B) DN group: Kidney of rat from the 
positive control group with thickened glomerular basement membrane, effacement of podocyte foot processes 
and reduction of the foot processes hiatus number; (C) TG1 group: Treating DN rats with TG (5 mg/kg/d) reduced 
the above-mentioned renal damage; (D) TG2 group: Treating DN rats with a higher dose of TG (10 mg/kg/d) 
restored the above-mentioned renal damages to some extent. 
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Effect of TG on expressions of MCP-1 and 
CTGF in kidney tissues 
 
To investigate the effect of TG on expression of 
MCP-1 and CTGF in DN rats, 
immunohistochemistry, western blot and PCR 
analysis were performed. Immunohistochemical 
staining of MCP-1 and CTGF in kidney tissues 
were mainly localized to the glomeruli and 
tubulointerstitial revealing a significant increase 
in the DN rats, compared with the NC rats. The 
increase of MCP-1 and CTGF expression in the 
kidney of the DN rats was attenuated after 
treatment with TG (Figure 3 and 4).  
 
Quantitative analysis of these images showed 
that the expressions of MCP-1 and CTGF in the 
rats of DN group were significantly increased (p 
< 0.01), compared with the NC group, and the 
expressions of MCP-1 and CTGF in the rats of 
TG1 and TG2 group were significantly decreased 
(p < 0.01), compared with the DN group (Table 
2). The result of western blot analysis was similar 
with the immunohistochemistry result. We also 
quantified MCP-1 and CTGF mRNA expression 
in kidney tissues of all the groups (Figure 6). RT-
PCR analysis showed that the expressions of 
MCP-1 and CTGF mRNA in the kidney of rats of 
the DN group were also significantly increased (p 
< 0.01), compared with the normal control rats. 
TG significantly reduced these DN-induced 
increases in the expressions of MCP-1 and 
CTGF (p < 0.01) (Figure 5). This result 
demonstrated that TG prevents the expressions 
of MCP-1 and CTGF in rats with diabetic 
nephropathy. 
 
Effect of TG on infiltration of macrophages 
 
To evaluate the infiltration of macrophages in the 
different groups, immunohistochemical staining 
for the macrophage marker ED-1 was performed. 
As shown in Figure 7 and Table 2, the number of 
ED-1 positive cells increased significantly in the 
kidney of DN group (p < 0.01), compared with 
the NC group. After treatment with TG, the 
number of ED-1 positive cells in TG1 and TG2 
group were decreased significantly (p < 0.01), 





Figure 3: Immunohistochemical staining of MCP-1 in the kidney of different groups (400× magnification); (A) NC 
group: rat kidneynshowed no brown immunopositive deposits; (B) DN group: Brown immunopositive deposits 
were largely localized to the glomeruli and tubulointerstitial; (C) TG1 group: Treating DN rats with TG (5 mg/kg/d) 
reduced the immunopositive deposits; (D) TG2 group: Treating DN rats with TG (10 mg/kg/d) reduced the 
immunopositive deposits 
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Figure 4: Immunohistochemical staining of CTGF in the kidney of different groups (400× magnification). (A) NC 
group: Kidney of the rats showed no brown immunopositive deposits; (B) DN group: Brown immunopositive 
deposits were largely localized to the glomerular and tubulointerstitial; (C) TG1 group: Treating DN rats with TG 
(5 mg/kg/d) reduced the immunopositive deposits; (D) TG2 group: Treating DN rats with TG (10 mg/kg/d) 
reduced the immunopositive deposits 
 
 




Figure 6: Effect of TG treatment on the expressions of CTGF and MCP-1 mRNA in the kidney. Real-time PCR 
analysis of the CTGF and MCP-1 genes expression in rats of NC, DN and treated with TG groups (TG1 and TG2 
group) 
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Figure 7: Immunohistochemical staining of ED-1 in the kidney of different groups (400× magnification); (A) NC 
group: Kidney of the rats showed small amount of brown immunopositive deposits; (B) DN group: Brown 
immunopositive deposits were largely localized to the glomerular and tubulointerstitial; (C) TG1 group: Treating 
DN rats with TG (5 mg/kg/d) reduced the immunopositive deposits; (D) TG2 group: Treating DN rats with TG (10 




In the last decade, researchers have 
demonstrated that inflammation and alterations 
in the immune system play important roles in the 
occurrence and development of DN [1]. MCP-1 is 
one of the important inflammatory chemokines 
for promoting interstitial inflammation, and is 
found to correlate with severity of the disease in 
a variety of renal diseases [4].  
 
Infiltration of mononuclear macrophages can 
stimulate innate renal cell activation and 
proliferation, which can promote the progression 
of kidney damage, increase the synthesis and 
aggregation of type I, III and IV collagen, induce 
the expression of adhesion molecules, increase 
the release of lysosomal enzymes and TGF, 
increase the expression of ECM protein and 
promote the development of glomerular sclerosis 
and interstitial fibrosis.  
 
CTGF is an immediate early gene belonging to 
the CCN protein family, and is highly expressed 
in the kidney. It’s demonstrated that CTGF play a 
key role in DN caused by renal interstitial fibrosis 
and glomerulosclerosis, and could be a major 
cause of kidney damage in diabetes [5]. Urinary 
level of MCP-1 was observed to be significantly 
increased and was found to correlate with the 
degree of renal interstitial fibrosis and tubular 
atrophy [6]. Additionally, it was confirmed that 
urinary CTGF level could act as a sensitive early 
indicator of renal injury. The fact that the 
concentration of urinary CTGF was positively 
correlated with the severity of disease makes it 
helpful to detect, diagnose, and monitor the 
progression of DN [7,8].  
 
Many previous studies have shown that 
glomerulosclerosis is associated with 
macrophage infiltration in DN, and the 
expressions of MCP-1 and CTGF in mesangial 
cell were involved in the development of DN 
[7,9], suggesting that MCP-1 and CTGF play 
important roles in the pathogenesis of this 
disease. Thus, MCP-1 and CTGF are potential 
targets for treating DN, and inhibiting the 
expressions of MCP-1 and CTGF might be 
beneficial for treating DN. Our results also 
demonstrated that expressions of MCP-1 and 
CTGF were related to the early renal damages of 
DN rats, and macrophages secreted many pro-
fibrotic molecules after entering into the glomeruli 
and tubulointerstitial area under the chemotactic 
effect of MCP-1, which in turn promote renal 
interstitial fibrosis.  
 
These results are consistent with the previous 
results of Wada [10]. In this study, we found that 
TG treatment could down-regulate the 
expressions of MCP-1 and CTGF in kidney and 
inhibit the macrophage infiltration. In addition, TG 
can suppress immune response, inhibit the 
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proliferation of mesangial cells and matrix, and 
delay the progression of glomerulosclerosis in 
DN. Furthermore, TG can alleviate the renal 
tubular damage via inhibiting the releases of 
inflammatory mediators and cytokines in renal 
tubular epithelial cells (TECs). Thus, TG 
possesses promising protective effect on 
glomerular podocytes and tubular epithelial cells. 
Previous investigations reported that extracts of 
Tripterygium wilfordii Hook f (i.e. triptolide) could 
suppress the increase of MCP-1 in renal tubular 
epithelial cells caused by multiple stimuli [11]. 
The protective effect of TG on the kidneys of 
diabetic rats may be related to the reduction of 
CTGF in kidney [12]. Clinical studies also found 
that TG could significantly reduce proteinuria in 
DN, delay the onset of disease, and TG was 
reported to be more effective than the 
angiotensin receptor blocker (ARBs) drugs [13]. 
However, the specific mechanisms of TG still 
need further study.  
 
It has been reported that infiltration of 
macrophage and abnormal expressions of 
inflammatory factors are important features of 
early inflammatory response in DN, and the 
macrophage is the main target of TG for treating 
DN [14]. In the present study, we found that 
expressions of CTGF and MCP-1 in DN rats 
were increased significantly, compared with that 
of normal rats. After treatment with TG, the 
infiltration of macrophage and expressions of 
CTGF and MCP-1 in kidney were decreased 
significantly. All these results suggested that TG 
could reduce kidney damage through down-
regulating the expressions of CTGF and MCP-1, 
and decreasing the infiltration of macrophage.  
 
We have further revealed that TG could inhibit 
the abnormal expressions of CTGF and MCP-1 
in the early stages of DN rats, suggesting that 
TG might reduce glomerular injury through 
inhibiting aggregation and activated anti-
inflammatory effects of macrophage. High-dose 
(10 mg/kg/d) TG was observed to be more 
effective than the low-dose TG (5 mg/kg/d) in 
down-regulating the expressions of CTGF and 
MCP-1, especially the CTGF. Furthermore, 
expressions of Scr and BUN decreased after TG 
treatment, suggesting that TG may improve the 
nutritional status of DN rats.  The BG of rats 
increased after induction of DN, by the increase 
was reversed by treatment with TG. Moreover, 
high dose of TG (10 mg/kg) affected the lipid 
level of the rats by increasing total cholesterol 
and triglycerides. However, this result is not quite 
in line with a previous study [15]. Thus further 
experimental and clinical studies were needed, 
and it is worth mentioning that dyslipidemia, in 
addition to the traditional TG adverse effects, 




MCP-1 and CTGF play key roles in the 
occurrence and development of DN. TG exhibits 
notable protective effect against renal damage 
via inhibition of the expressions of MCP-1 and 
CTGF and reduction of macrophage activation. 
It, therefore, requires further development for 
treatment of early DN. 
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